DIRS.INFO The most relevant business & tech news

Major equity indexes have been largely stable during the early stages of a first-quarter earnings season that investors expect to show tepid results. The Dow Jones Industrial Average (.DJI) fell 79.62 points, or 0.23%, to 33,897.01; the S&P 500 (.SPX) lost 0.35 points, or 0.01%, at 4,154.52; and the Nasdaq Composite (.IXIC) added 3.81 points, or 0.03%, at 12,157.23. The defensive utilities group (.SPLRCU) gained most among S&P 500 sectors, rising 0.8%. S&P 500 companies overall are expected to post a 4.8% decline in first-quarter earnings from the year-earlier period, according to Refinitiv IBES. The S&P 500 posted 16 new 52-week highs and one new lows; the Nasdaq Composite recorded 59 new highs and 123 new lows.

Major equity indexes have been largely stable during the early stages of a first-quarter earnings season that investors expect to show tepid results. The defensive utilities group (.SPLRCU) gained most among S&P 500 sectors, rising 0.7%. S&P 500 companies overall are expected to post a 4.8% decline in first-quarter earnings from the year-earlier period, according to Refinitiv IBES. Shares of Western Alliance Bancorp (WAL.N) surged 23% after the company posted stronger-than-expected earnings, helping lift the SPDR S&P Regional Banking ETF (KRE.P) 4%. The S&P 500 posted 15 new 52-week highs and one new low; the Nasdaq Composite recorded 48 new highs and 111 new lows.

☆ Abbott Labs shares pop as revenue, earnings defy steep drop in Covid test sales
▼ + stars: | 2023-04-19 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Shares of Abbott Laboratories popped Wednesday after the company's earnings and revenue topped Wall Street's expectations, defying a dramatic slowdown in sales of its Covid-19 tests. Abbott reported revenue of $9.7 billion for the first quarter, slightly surpassing the Refinitiv estimate of $9.64 billion due to recovery in its medical devices business. Strong sales in Abbott's medical devices business fueled the company's first-quarter beats. The unit raked in $3.9 billion in sales during the quarter, up nearly 9% from the same period last year. That comes after rival Johnson & Johnson reported strong growth in its own medical devices unit, noting that surgical procedures are "well in recovery."

☆ Investors who do their homework can find good opportunities in a skittish market, Jim Cramer says
▼ + stars: | 2023-04-19 | by ( Rohan Goswami | In Rohangoswamicnbc | ) www.cnbc.com time to read: +1 min

Three companies that saw trading swing on earnings this week showcased opportunities for investors who can look past early bias and buy in when the rest of the market is skittish, CNBC's Jim Cramer said Wednesday. "The actual hitters, the people who do enough homework" are able to step up and win while other investors sell off or hold themselves back amid morning lows, Cramer said. Morgan Stanley , for example, reported earnings on Wednesday morning showing a higher-than-expected loan loss provision. In Big Pharma, Abbott Labs reported an "incredible quarter" on Wednesday with good performance on every line, Cramer said, adding that coverage underplayed the company's performance. Once investors were able to digest the full earnings presentation, Cramer said, Abbott's stock "powered higher."

☆ Morning Bid: Crowded bonds unnerved
▼ + stars: | 2023-04-19 | by ( ) www.reuters.com time to read: +5 min

This has some wondering if the recent dash for cash and top-rated bonds has become a bit crowded and how much more tightening central banks have to do. As we move into the weeds of the first-quarter U.S. earnings season, it's been a mixed bag so far. That clearly unnerved UK government bonds - where 10 year yields jumped 10bps - but it also jarred sovereign bonds around the world. Elsewhere, further signs of healing were evident in the global bank funding market. Japan's Sumitomo Mitsui Financial Group (8316.T) sold $1 billion of additional tier-1 debt, the first major global bank to sell the risky securities since similar bonds issued by Credit Suisse were wiped out last month.

☆ Earnings from Club consumer, health and bank stocks will be our main focus in the week ahead
▼ + stars: | 2023-04-15 | by ( Zev Fima | ) www.cnbc.com time to read: +7 min

Corporate earnings won't have to share the spotlight with major inflation data in the week ahead as they did during this past week's up-and-down market. From Morgan Stanley, we suspect Friday's bank earnings foreshadow a good release. This past week, we spoke about the importance of listening to what industry players aside from those you're invested in as a way to analyze the competitive landscape. Here are some of those other earnings reports and the economic numbers out in the week ahead. Club trades of the week We made just one trade this past week, in a market that was overbought , purchasing 25 shares of Palo Alto Networks (PANW).

☆ Here are Tuesday's biggest analyst calls: Apple, Tesla, Dick's, Costco, Snowflake, Meta, Dish & more
▼ + stars: | 2023-02-28 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Here are Tuesday's biggest calls on Wall Street: Mizuho reiterates Tesla as buy Mizuho said it's standing by its buy rating heading into the company's analyst day on March 1. Barclays reiterates Apple as equal weight Barclays said low growth in the App Store is the "new norm" for Apple. Morgan Stand reiterates Dick's as overweight Morgan Stanley said it's standing by its overweight rating heading into Dick's earnings on March 7. Bank of America downgrades Dish to underperform from buy Bank of America said it sees inflationary pressure for the satellite TV company. Deutsche Bank reiterates Salesforce as buy Deutsche Bank said it's standing by shares of Salesforce heading into earnings on Wednesday.

☆ Lightning Round: Pfizer's got a weaker pipeline than we thought
▼ + stars: | 2023-02-28 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailLightning Round: Pfizer's got a weaker pipeline than we thoughtMad Money host Jim Cramer weighs in on all manner of stocks, including Eli Lilly, Abbott Labs, Analog Devices, Pfizer, ADMA Biologics, Freyr Battery SA and Barrick Gold.

☆ Final Trades: Abbott Labs, GE Healthcare, Viper Energy and more
▼ + stars: | 2023-01-23 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: Abbott Labs, GE Healthcare, Viper Energy and moreThe "Halftime Report" traders give their top picks to watch for the second half.

☆ Stocks making the biggest moves premarket: Wayfair, Salesforce, Paypal and more
▼ + stars: | 2023-01-23 | by ( Michelle Fox | ) www.cnbc.com time to read: +3 min

Check out the companies making the biggest premarket moves:Advanced Micro Devices — The semiconductor maker rallied nearly 3% after being upgraded by Barclays to overweight from equal weight. The Wall Street firm cited improving market share trends and a better grasp on spending from management. Abbott Laboratories — Abbott Labs lost 2.5% following a Wall Street Journal report Friday that the Justice Department is investigating conduct at its infant-formula plant in Sturgis, Michigan. Tapestry — The Coach and Kate Spade parent slid 1.85% after being downgraded to equal weight from overweight by Barclays. The Wall Street firm's reasons included inflation creeping to higher household income brackets.

☆ Did the economy end 2022 with a bang or a whimper?
▼ + stars: | 2023-01-22 | by ( Paul R. La Monica | ) edition.cnn.com time to read: +7 min

But the United States economy still seems to be chugging along just fine after experiencing a hiccup in the first half of 2022. Despite worries about weaker consumer spending during the holidays, economists are forecasting solid growth for the fourth quarter. Yearning for earningsMore blue chip companies will report fourth quarter results (and perhaps give guidance about the first quarter of 2023 and beyond) this week. But according to FactSet senior earnings analyst John Butters, earnings for the tech sector are expected to fall nearly 10% in the fourth quarter compared to the fourth quarter of 2021. Verizon (VZ), Johnson & Johnson (JNJ), Travelers (TRV), 3M (MMM), Boeing (BA), Dow (DOW), Visa (V), Chevron (CVX) and American Express (AXP).

☆ After baby formula problems, Abbott Laboratories under DOJ investigation
▼ + stars: | 2023-01-21 | by ( Laura Strickler | Laura Strickler Is A Senior Investigative Producer | Reporter For Nbc News. She Is Based In Washington. | ) www.nbcnews.com time to read: +2 min

Abbott Laboratories is under investigation by the U.S. Department of Justice, the company confirmed Friday, almost a year after it shut down a Michigan baby-formula plant after illnesses were reported. Abbott did not specify what aspect of the company is under Justice Department scrutiny. “DOJ has informed us of its investigation and we’re cooperating fully,” an Abbott spokesperson said in a statement to NBC News. The Abbott manufacturing facility in Sturgis, Mich., on May 13, 2022. Abbott voluntarily shut down production at its Sturgis infant formula manufacturing plant on Feb. 17, 2022, after infants who consumed formula made at the plant became sick.

☆ Get ready for a deluge of data next week that will shape the Fed's next moves
▼ + stars: | 2023-01-21 | by ( Zev Fima | ) www.cnbc.com time to read: +8 min

Within the portfolio, we'll get the latest earnings from Danaher (DHR), Halliburton (HAL), and Johnson & Johnson (JNJ) on Tuesday before the opening bell. While the results will be important as always, we are most interested in the earnings call with analysts and investors. Housing Starts fell 1.4% in December to a seasonally adjusted annual rate of 1.38 million, slightly above the 1.36 million expected. Building permits dropped 1.6% in December to a seasonally adjusted annual rate of 1.33 million, below expectations of 1.37 million. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

☆ Earnings could keep the market on edge in week ahead as investors wait for Fed
▼ + stars: | 2023-01-20 | by ( Patti Domm | In | ) www.cnbc.com time to read: +8 min

I do think that will happen even more in the week ahead as the Fed is in a blackout period. S & P Global PMI data is released for both services and manufacturing Tuesday. "The market continues to think the Fed does not have to administer as much medicine as the Fed tells us they plan to. Earnings, earnings, earnings Stocks were lower in the past week, with the S & P 500 off by 1.8%. "It's a mild earnings recession, but it's an earnings recession.

☆ Here are Tuesday's biggest analyst calls of the day: Tesla, Amazon, Alphabet, Carvana, Target & more
▼ + stars: | 2022-10-18 | by ( Michael Bloom | ) www.cnbc.com time to read: +5 min

Wedbush downgrades Carvana to neutral from buy Wedbush said in its downgrade of Carvana that it sees severe cash burn and deteriorating market conditions. Jefferies upgrades Target to buy from hold After a change in analyst coverage, Jefferies upgraded the big box retailer and said it sees "margin improvement." Goldman Sachs reiterates Chipotle as buy Goldman said the stock is too compelling to ignore heading into earnings next week. " Deutsche Bank reiterates Microsoft as buy Deutsche Bank said Microsoft is still the "best house on the block" heading into earnings next week. " Barclays reiterates Amazon as overweight Barclays sad investors should buy the stock ahead of earnings later this month.

☆ Tesla investors try to ignore Musk's many distractions
▼ + stars: | 2022-10-16 | by ( Paul R. La Monica | ) edition.cnn.com time to read: +7 min

While that’s good news for Twitter’s long-suffering shareholders, Tesla investors hope he still has some time for them. There are big challenges in China as well, with Tesla going up against homegrown EV rivals like Nio (NIO), Xpeng and Li Auto. Too many distractionsGary Black, managing partner at the Future Fund and a Tesla shareholder, has been tweeting for the past few weeks that concerns about Twitter are a headache for Tesla investors. In one tweet, Black said there are several problems for Tesla due to Twitter. The underwhelming deliveries and production numbers also underscore how a slowing global economy (and possible recession) could hurt Tesla.

Search resuls for: "Abbott Labs"

16 mentions found